Sanofi (SNY) Receivables (2009 - 2026)

Sanofi has disclosed Receivables across 18 years of filings, most recently posting $10.1 billion for Q2 2026.

• In Q2 2026, Receivables rose 14.57% year-over-year to $10.1 billion; the TTM figure through Jun 2026 stood at $10.1 billion (up 14.57% YoY), while the FY2025 annual figure was $9.8 billion, up 17.82% from the prior year.
• Receivables came in at $10.1 billion for Q2 2026 at Sanofi, down from $27.5 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $28.6 billion in Q3 2025 to a low of $8.2 billion in Q4 2024.
• Average Receivables over 5 years is $13.4 billion, with a median of $9.1 billion recorded in 2023.
• Year-over-year, Receivables decreased 9.59% in 2024 and gained 19.72% in 2026.
• Over 5 years, Receivables stood at $8.6 billion in 2022, then advanced by 5.57% to $9.1 billion in 2023, then dropped by 9.59% to $8.2 billion in 2024, then rose by 19.33% to $9.8 billion in 2025, then grew by 3.47% to $10.1 billion in 2026.
• Per Business Quant data, the three most recent Receivables figures were $10.1 billion in Q2 2026, $27.5 billion in Q1 2026, and $9.8 billion in Q4 2025.